Jade Biosciences, Inc.
NASDAQ: JBIO
(Source: TradingView) 3-months Performance Profile of JBIO on a DTF compared to Dow Jones Industrial Average (DJI) and S&P 500 (SPX).
Jade Biosciences is progressing a differentiated autoimmune pipeline, backed by a strong cash position of ~$336 million, providing funding visibility into 1H 2028. Its lead programs, JADE101 (anti-APRIL) and JADE201
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
